CJC-1295 with DAC and Ipamorelin Interaction
CJC-1295 with DAC and Ipamorelin have an interaction requiring monitoring for interaction with 90% confidence. Continuous GH elevation may reduce synergistic benefits of pulsatile protocols. Both compounds affect the gi tract and pituitary, so monitoring these systems is recommended.
Compound Profiles
CJC-1295 with DAC
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation..
View full profileIpamorelin
Growth Hormone Secretagogue | Selective GHRP
Binds selectively to ghrelin receptors in pituitary gland, stimulating natural GH release with direct systemic delivery via injection, consistent GH pulse stimulation, no significant cortisol or prolactin elevation, and minimal hunger response..
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC-1295 with DAC with Ipamorelin?
Yes, but with caution. Continuous GH elevation may reduce synergistic benefits of pulsatile protocols. Regular monitoring is advised.
Is CJC-1295 with DAC and Ipamorelin safe together?
Based on documented research, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting. Monitor accordingly.
What are the interactions between CJC-1295 with DAC and Ipamorelin?
Continuous GH elevation may reduce synergistic benefits of pulsatile protocols. This assessment has 90% confidence and is based on documented research data.
How should I time CJC-1295 with DAC and Ipamorelin?
CJC-1295 with DAC has a half-life of 6-8 days and Ipamorelin has a half-life of ~2 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.